Genmab — August 2024
-
Godmorgen
-
Aug. 6, 2024,
Ram Selvaraju, H.C. Wainwright, reiterated the Buy rating on Genmab. The price target remains the same with $50.00. "Despite BioNTech’s decision to step back from the co-development of acasunlimab, Selvaraju’s confidence in the drug remains unshaken, as he finds the clinical results presented at ASCO 2024 to be highly encouraging." https://markets.businessinsider.com/news/stocks/buy-rating-affirmed-for-genmab-strong-clinical-results-and-solid-financial-valuation-1033645523 -
TEPEZZA
(teprotumumab-trbw) generated $479 million of sales in the second quarter. AMGEN REPORTS SECOND QUARTER 2024 https://investors.amgen.com/news-releases/news-release-details/amgen-reports-second-quarter-2024-financial-results -
Regulatory review of the New Drug Application (NDA) for TEPEZZA in Japan and multiple additional geographies continues.
A Phase 3 study of TEPEZZA in Japan continues to enroll patients with chronic or low clinical activity score TED.
A Phase 3 study evaluating the subcutaneous route of administration of TEPEZZA is enrolling patients with TED. -
Today, Exelixis announced it will discontinue the development of XB002, the company’s tissue factor (TF)-targeting ADC, as part of its portfolio prioritization efforts. Based on available data, the compound is unlikely to improve upon tisotumab vedotin or other competitor TF-targeting ADCs currently in development. https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-second-quarter-2024-financial-results-and
-
Burde Genmab aktien egentlig ikke have steget, ovenpå udmeldingen at Biontech trak sig fra Gen1046?.... Er klar over at det selvfølgelig giver usikkerhed, når en partner trækker sig for et stof .Men at Genmab ikke går ud og søger ny aftale, eller selv overvejer at trække stikket fortæller jo også en hel del. - Tværtimod vælger Genmab selv at stå for udgifterne på et dyrt fase 3 forsøg. Hvilket må tolkes til at Genmab tror selv meget på stoffet, - og så må det jo egentlig være en gave at stå med
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind